Orlando Veterans Affairs Stratification Tool for Opioid Risk Mitigation (STORM) very high risk interdisciplinary team review: A brief report.
| Autor: | Hundley L, Nguyen D, Alexander A, Moore M, Coakley C, Nguyen T, Szabo J, Reno-Ly K |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the American Pharmacists Association : JAPhA [J Am Pharm Assoc (2003)] 2024 Nov-Dec; Vol. 64 (6), pp. 102250. Date of Electronic Publication: 2024 Sep 12. |
| DOI: | 10.1016/j.japh.2024.102250 |
| Abstrakt: | Background: Compared to the general population, Veterans Health Administration (VHA) patients have higher rates of mental illness, chronic pain, and substance use disorders (SUD), conditions that increase risk for opioid-related adverse events. VHA developed the Stratification Tool for Opioid Risk Mitigation (STORM) and mandated case reviews by an interdisciplinary team (IDT) for patients identified as very high risk, a process implemented and led by clinical pharmacist practitioners at the Orlando Veterans Affairs Healthcare System (OVAHCS) in 2018. Objective: To evaluate and describe the implementation and process for IDT reviews of patients identified as very high risk by the STORM clinical decision support tool at OVAHCS. Methods: A single center, retrospective, observational chart review was conducted. Veterans reviewed by the STORM IDT between January and September 2018 were reviewed for change in Morphine Equivalent Daily Dose (MEDD), naloxone, nonopioid analgesics, medications for SUD, benzodiazepines, engagement with clinical services (e.g., mental health, SUD, and pain clinic), and overdose or suicide attempts in the year prior versus the year after IDT review. The frequency of follow-up IDT reviews was evaluated. Results: Seventeen patients were identified. Four were excluded due to nonopioid related death within 12 months after review. The average baseline MEDD was 82.2 mg (range 10-496 mg) and average 12 months after review was 7.5 mg (range 0 - 67.5 mg), a decrease of 74.7 mg, or 90.9% reduction. An increase in medications for SUD (3 patients; 23%), SUD engagement (3 to 6 patients), and urine drug tests was observed (79% increase). Benzodiazepine use decreased by 50%. Conclusion: This report provides insight on the IDT case review process at OVAHCS, a process that may vary widely across facilities. A reduction in MEDD, increase in SUD treatment, and improved risk mitigation was observed. The central role of clinical pharmacy and expanded process for continued follow-up warrants further study. Competing Interests: Disclosure The authors declare no relevant conflicts of interest or financial relationships. (Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|